<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03511638</url>
  </required_header>
  <id_info>
    <org_study_id>S877</org_study_id>
    <nct_id>NCT03511638</nct_id>
  </id_info>
  <brief_title>Bausch &amp; Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)</brief_title>
  <official_title>A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, controlled, randomized, monocular trial evaluating the safety and&#xD;
      effectiveness of the Bausch &amp; Lomb DVisc40 dispersive OVD compared to the Alcon VISCOAT®&#xD;
      dispersive OVD when used in cataract surgery. Subjects will be randomized to one of the two&#xD;
      treatment groups in a 1:1 ratio (DVisc40:VISCOAT®).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2018</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a multicenter, controlled, randomized, monocular trial of Bausch &amp; Lomb DVisc40 (test) OVD compared to the currently marketed Alcon VISCOAT® (control) OVD</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Mean Epithelial Cell Density (ECD)</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Postoperative Intraocular Pressure of at Least 30 mm Hg</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Bausch &amp; Lomb DVisc40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ophthalmic viscosurgical device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcon VISCOAT®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ophthalmic viscosurgical device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bausch &amp; Lomb DVisc40</intervention_name>
    <description>Ophthalmic viscosurgical device</description>
    <arm_group_label>Bausch &amp; Lomb DVisc40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alcon VISCOAT®</intervention_name>
    <description>Ophthalmic viscosurgical device</description>
    <arm_group_label>Alcon VISCOAT®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must be at least 45 years old and have a clinically documented diagnosis&#xD;
             of age-related non-complicated cataract that is considered amenable to treatment with&#xD;
             standard phacoemulsification cataract extraction and IOL implantation.&#xD;
&#xD;
             2. The subject must have the capability to provide written informed consent on the&#xD;
             Institutional Review Board (IRB)/Ethics Committee (EC) approved Informed Consent Form&#xD;
             (ICF) and provide authorization as appropriate for local privacy regulations.&#xD;
&#xD;
             3. The subject must be willing and able to return for all scheduled follow-up&#xD;
             examinations through 90 days following surgery.&#xD;
&#xD;
        Study #877 Protocol DVisc40 28JUL2017 V1.0 CONFIDENTIAL Page 16 of 53 4. The subject must&#xD;
        have clear intraocular media other than the cataract in the operative eye.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. The subject has participated in any drug or device clinical investigation within 30&#xD;
             days prior to entry into this study and/or during the period of study participation.&#xD;
&#xD;
             2. The subject has any corneal pathology (e.g., significant scarring, guttata,&#xD;
             inflammation, edema, dystrophy, etc.) in the operative eye.&#xD;
&#xD;
             3. The subject has anterior segment pathology likely to increase the risk of an&#xD;
             adverse outcome for phacoemulsification cataract surgery (e.g., pseudoexfoliation&#xD;
             syndrome, synechiae, iris atrophy, inadequate dilation, shallow anterior chamber,&#xD;
             traumatic cataract, lens subluxation) in the operative eye.&#xD;
&#xD;
             4. The subject has any condition which prevents reliable specular microscopy in the&#xD;
             operative eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anya Loncaric</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Valeant Site 01</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>22434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <results_first_submitted>September 24, 2021</results_first_submitted>
  <results_first_submitted_qc>September 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <disposition_first_submitted>October 23, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>October 23, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 5, 2019</disposition_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03511638/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bausch &amp; Lomb DVisc40</title>
          <description>Ophthalmic viscosurgical device&#xD;
Bausch &amp; Lomb DVisc40: Ophthalmic viscosurgical device</description>
        </group>
        <group group_id="P2">
          <title>Alcon VISCOAT®</title>
          <description>Ophthalmic viscosurgical device&#xD;
Alcon VISCOAT®: Ophthalmic viscosurgical device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bausch &amp; Lomb DVisc40</title>
          <description>Ophthalmic viscosurgical device&#xD;
Bausch &amp; Lomb DVisc40: Ophthalmic viscosurgical device</description>
        </group>
        <group group_id="B2">
          <title>Alcon VISCOAT®</title>
          <description>Ophthalmic viscosurgical device&#xD;
Alcon VISCOAT®: Ophthalmic viscosurgical device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="184"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="372"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" lower_limit="47" upper_limit="86"/>
                    <measurement group_id="B2" value="69.0" lower_limit="45" upper_limit="86"/>
                    <measurement group_id="B3" value="70.0" lower_limit="45" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="258"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Study eye - right or left</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Right Eye</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Left Eye</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Mean Epithelial Cell Density (ECD)</title>
        <time_frame>Day 90</time_frame>
        <population>Participants with epithelial cell density at baseline and Day 90 were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bausch &amp; Lomb DVisc40</title>
            <description>Ophthalmic viscosurgical device&#xD;
Bausch &amp; Lomb DVisc40: Ophthalmic viscosurgical device</description>
          </group>
          <group group_id="O2">
            <title>Alcon VISCOAT®</title>
            <description>Ophthalmic viscosurgical device&#xD;
Alcon VISCOAT®: Ophthalmic viscosurgical device</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Mean Epithelial Cell Density (ECD)</title>
          <population>Participants with epithelial cell density at baseline and Day 90 were included in the analysis.</population>
          <units>percentage change in ECD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="12.19"/>
                    <measurement group_id="O2" value="-6.8" spread="12.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Postoperative Intraocular Pressure of at Least 30 mm Hg</title>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bausch &amp; Lomb DVisc40</title>
            <description>Ophthalmic viscosurgical device&#xD;
Bausch &amp; Lomb DVisc40: Ophthalmic viscosurgical device</description>
          </group>
          <group group_id="O2">
            <title>Alcon VISCOAT®</title>
            <description>Ophthalmic viscosurgical device&#xD;
Alcon VISCOAT®: Ophthalmic viscosurgical device</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Postoperative Intraocular Pressure of at Least 30 mm Hg</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4"/>
                    <measurement group_id="O2" value="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bausch &amp; Lomb DVisc40</title>
          <description>Ophthalmic viscosurgical device&#xD;
Bausch &amp; Lomb DVisc40: Ophthalmic viscosurgical device</description>
        </group>
        <group group_id="E2">
          <title>Alcon VISCOAT®</title>
          <description>Ophthalmic viscosurgical device&#xD;
Alcon VISCOAT®: Ophthalmic viscosurgical device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior capsule rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Punctate keratitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="188"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Please contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch &amp; Lomb</organization>
      <phone>510-259-5284</phone>
      <email>aloncaric@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

